Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell receives milestone payment from partner Merck & Co., Inc. for bacterial vaccine candidate

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 02.11.2005 Intercell AG (VSE, "ICLL") announced today that it has received a milestone payment of USD 1 million from Merck & Co., Inc. for significant progress made in the development of a bacterial vaccine candidate. The vaccine candidate, which has the potential to address an unmet medical need in the field of infectious diseases, was licensed from Intercell under a collaboration and license option agreement signed in May 2004. The parties have agreed confidentiality on the indication. The vaccine candidate is expected to enter clinical development in the near future. "We’re pleased that Merck, which has a reputation as a leader and innovator in the field of vaccines, has made significant progress in the development of a vaccine candidate that is fully derived from our bacterial Antigen Identification Program," said Gerd Zettlmeissl, CEO of Intercell AG. "This is an example of the valuable role Intercell technologies can play in developing potential vaccines." About Intercell Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unaddressed medical need. The Company’s unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell’s technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For more information please visit: www.intercell.com This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. end of announcement euro adhoc 02.11.2005 07:38:56 -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.de Further inquiry note: Intercell AG Mag. Katharina Wieser Head of Corporate Communications Tel. +43 1 20620-303 kwieser@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: Börsen: Wiener Börse AG / official market

Das könnte Sie auch interessieren: